Navigation Links
Long-term 12-month safety data on ADHD patch DAYTRANA
Date:10/26/2007

BOSTON OCTOBER 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years. The study data was presented today at a major scientific and educational meeting of child and adolescent psychiatrists held in Boston, and is consistent with data previously presented.

In our study, children with ADHD experienced effective ADHD symptom control improvement when using DAYTRANA for 12 months, improving their ability to maintain focus and concentration in and outside of the classroom, reported investigator Frank A. Lpez, M.D., neurodevelopmental pediatrician at the Childrens Developmental Center, Winter Park, Fla. Importantly, this year-long study showed that DAYTRANA maintained a favorable safety profile throughout the study period, with adverse events consistent with previous DAYTRANA studies.

Shires DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. The study results demonstrate that adverse events associated with DAYTRANA were similar to other methylphenidate products. The most common adverse events reported in this study were decreased appetite, headache, upper respiratory tract infection, cough, fever, and decreased weight. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping.

Lpez added, DAYTRANAs novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their childrens changing schedules.

While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re-evaluate patients to assess the usefulness of DAYTRANA for the individual patient.

The study was supported by funding from Shire.


'/>"/>

Contact: Jennifer Anello
212-601-8132
Porter Novelli
Source:Eurekalert

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Long-Term Survival can be Predicted by a Simple Lung Test
3. Small lumps in breast if not treated may cause long-term harm
4. Lung Therapy Found To Have Long-Term Side Effects
5. Long-Term Benefits Of Statins Questioned
6. Long-term use of calcium supplements to prevent colon cancer
7. Survivors of childhood cancer may have long-term health problems
8. Long-term Care Should Be A Planned Affair
9. Pfizer vouches safety of long-term inhaled insulin.
10. Clue to Link Between Obesity and Long-Term Memory Discovered
11. Drug Regulators Need To Think In Long-Term, Say Charities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... A July ... lead to, or worsen, varicose veins in some patients, according to medical experts. ... certain not-so-good practices, like excessive sitting or standing, or regularly nicking yourself while ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Lucky the Buffalo and Her Adventures”: a collection of heartwarming children’s ... Bieniek. Edward Steven Bieniek Jr. was born in Toledo, Ohio. He attended Woodward ... tech. He is married to a brilliant woman with a caring heart named Tiina, ...
(Date:7/18/2017)... ... July 18, 2017 , ... Cognition Corporation , ... two more sessions of its “From the Helm” Webinar Series. , These ... David Cronin, Cognition’s CEO, the half-hour public webinars will take an in-depth look ...
(Date:7/18/2017)... ... ... of an international clinical trial, led in part by a UC Davis School of Medicine ... promise for a subgroup of patients. , In a paper just published online in the ... in 18 countries describe the clinical benefit of using the drug ataluren for a certain ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Anacortes, ... "Due to menopause, I have frequent hot flashes, and I suffer from anxiety and ... way to keep cool while out and about." INSTA-FAN meets that need. , This ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... , July 13, 2017 It should come ... States is in the midst of a crippling ... , since 1999, the number of overdose deaths from opiate-based ... in over half a million dead from 2001 to 2015". ... oxycodone, and hydrocodone has similarly quadrupled, drawing a compelling link ...
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful ... Carpal tunnel syndrome affects more than 8 million people a year. ... men. The common methods of treating CTS are painful surgery, the ... or gloves. ... CarpalAID is a clear patch worn on the palm of ...
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
Breaking Medicine Technology: